Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several dose/interval statements and monitoring/pregnancy/infection-management claims are not supported by the provided label excerpts or are inaccurate relative to the dosing and monitoring information shown. Overall alignment is partial.
Category Scores
Accurate Statements
Increase the COSENTYX dose to 300 mg every 4 weeks in adult patients with active Psoriatic Arthritis (PsA) who continue to have active disease.
Supported by provided label excerpt Dosage and Administration (2.4): “If a patient continues to have active PsA, consider increasing the dosage to 300 mg by subcutaneous injection every 4 weeks. Each 300 mg dosage is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.”
Unsupported Statements
There is no fixed frequency for monitoring dosage because Cosentyx uses fixed subcutaneous doses without routine blood level checks.
The provided label excerpts do not state anything about absence of routine blood level monitoring or that there is “no fixed frequency” for monitoring dosage; this claim is not supported by the included label text.
Clinicians assess clinical response after 12-16 weeks to decide continuation of Cosentyx.
The provided excerpts do not include a labeled instruction/timeline to reassess for continuation based on 12–16 weeks.
If response is inadequate, clinicians may increase the Cosentyx dose (e.g., from 150 mg to 300 mg) or switch therapies.
The provided excerpts support dose increase for active PsA (and consider increases for active AS/nr-axSpA), but do not broadly support a general “12–16 weeks response → increase or switch therapies” algorithm across indications or the “switch therapies” component.
Routine lab monitoring focuses on safety rather than dosage adjustment for Cosentyx.
The provided label excerpts do not describe lab monitoring for dosing adjustment vs safety framing.
Complete blood count, liver enzymes, and lipids should be monitored before starting Cosentyx.
The provided label excerpts include pre-treatment evaluations for TB and vaccinations, but do not mention CBC, liver enzymes, or lipids as specific monitoring to perform before starting.
Complete blood count, liver enzymes, and lipids should be monitored periodically after starting Cosentyx (e.g., every 3-6 months or as clinically indicated).
The provided label excerpts do not specify CBC/liver enzyme/lipid monitoring schedules.
Inflammatory bowel disease screening should occur before initiating Cosentyx due to risk of exacerbation.
The provided label excerpt discusses IBD exacerbations and recommends exercise caution and monitoring for signs/symptoms after treatment; it does not provide a pre-initiation screening mandate.
No specific timeline mandates dosage changes based on labs for Cosentyx; adjustments are based on efficacy or side effects.
The provided label excerpts do not discuss lab-based dosage change timelines.
At 12-16 weeks, poor response should prompt reassessment and dose escalation if partial improvement.
The provided label excerpts do not include a labeled rule for reassessment at 12–16 weeks to escalate dosing based on “partial improvement.”
Weight changes may affect pediatric dosing of Cosentyx but not adult dosing.
The provided excerpts state pediatric dosing is weight-based and adult dosing regimens are fixed by indication, but the specific comparative statement about adult dosing not being affected by weight is not explicitly stated in the provided label excerpts.
During pregnancy or breastfeeding, Cosentyx may be discontinued or adjusted based on risk-benefit.
The provided label excerpts for pregnancy and lactation discuss risk summaries/benefit considerations but do not state that COSENTYX “may be discontinued or adjusted” based on risk-benefit in a directive manner.
Contradictions
Low
AI Statement
For psoriatic arthritis and ankylosing spondylitis, Cosentyx is 150 mg (one injection) at the same intervals, or 300 mg if needed.
Label Reference
2.4 Recommended Dosage in Adults with Psoriatic Arthritis and 2.6 Recommended Dosage in Adults with Ankylosing Spondylitis: label states 150 mg dosing may be with or without a loading dosage (PsA) and provides explicit dosing regimens; the claim omits the labeled “with or without loading dosage” distinction and does not correctly describe the interval structure for the “with loading” regimen as “same intervals” without specifying the Weeks 0,1,2,3,4 loading plan. Severity: low
Low
AI Statement
Pediatric dosing for psoriasis with Cosentyx is adjusted by weight.
Label Reference
While weight-based pediatric dosing is supported for pediatric plaque psoriasis (2.3), the claim is partially imprecise relative to the provided label excerpts because it does not reflect the specific age cutoffs and exact weight bands/dose amounts. Severity: low
Low
AI Statement
Cosentyx doses should be held during active infections.
Label Reference
5.1 Infections: the excerpt says instruct patients to seek medical advice; if serious infection develops, monitor closely and discontinue COSENTYX until infection resolves. It does not state a blanket “hold during active infections.” Severity: low
Important Omissions
Loading dosage options (with/without loading) and explicit interval details for PsA, AS, and nr-axSpA are not consistently stated across the claims.
Importance:
Moderate
For infection-related guidance, the label excerpt specifically addresses active TB evaluation before initiation and provides “discontinue until resolved” for serious infection; the claim set does not reflect TB evaluation and uses an over-general infection-holding statement.
Importance:
Moderate
Pregnancy/lactation labeling provided focuses on risk summaries and benefit considerations; the claim does not reflect the label language about insufficient data/benefit considerations rather than a directive to discontinue/adjust.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some dosing details (loading vs no loading) and key safety monitoring/infection guidance are either imprecise or not supported by the provided label excerpts, and a blanket “hold during active infections” statement conflicts with the more specific label language about serious infections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (monitoring, infection handling, pregnancy/breastfeeding, reassessment timeline) are not supported by the supplied label excerpts; some dosing statements omit labeled loading-dose options.
Suggested Improvement
Restrict statements to what is explicitly present in the provided label sections (e.g., loading vs no loading dosing regimens; TB evaluation and vaccination prior to initiation; discontinue guidance specifically for serious infections; pregnancy/lactation risk summary language).